Press Release

NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain Neurostimulator

Supports Value of Insights Provided by Brain Recordings from the NeuroPace RNS® System for Drug-Resistant Epilepsy MOUNTAIN VIEW, Calif. – February 12, 2019 – NeuroPace, Inc., a…

NeuroPace Inc.February 12, 2019

Press Release

NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting

More than One-Third of Drug-Resistant Epilepsy Patients Achieved ≥90% Seizure Reduction with the RNS System. NEW ORLEANS--(BUSINESS WIRE)--American Epilepsy Society Annual Meeting, Booth 519 —…

NeuroPace Inc.December 2, 2018

Press Release

NeuroPace Launches Next Generation RNS System, the World’s Only Brain-Computer Interface for the Treatment of Refractory Epilepsy

Next Gen RNS System provides unprecedented brain data with long-lasting, 8-year battery life. MOUNTAIN VIEW, Calif -- June 1, 2018 – NeuroPace, Inc., a Silicon…

NeuroPace Inc.June 1, 2018

Press Release

NeuroPace Unveils 8-Year Prospective Clinical Outcomes and Groundbreaking Research Using Deep Learning Algorithms to Identify Seizure Biomarkers

WASHINGTON--(EON: Enhanced Online News)--American Epilepsy Society Annual Meeting, Booth 1101--NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop…

NeuroPace Inc.December 5, 2017

Press Release

NeuroPace Closes $74 Million Equity Funding to Accelerate Patient Access to the World’s First Brain-Responsive Neurostimulation System to Treat Epilepsy

MOUNTAIN VIEW, Calif. – October 24, 2017 – NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop brain-responsive…

NeuroPace Inc.October 23, 2017

Press Release

NeuroPace Announces 1,000th Patient Treated with RNS System for Medically Refractory Epilepsy

MOUNTAIN VIEW, California – February 20, 2017 – NeuroPace, Inc. announced today that the 1000th patient has been treated with its award-winning RNS® System, approved…

NeuroPace Inc.February 27, 2017

Press Release

NeuroPace, Inc. Announces Results of 7 Years of Clinical Trial Follow-up Demonstrating 72 Percent Seizure Reduction with the RNS® System – December 4, 2016

NeuroPace Inc.December 7, 2016

Press Release

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_UA-55828317-3	1 minute	A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
demdex	5 months 27 days	The demdex cookie, set under the domain demdex.net, is used by Adobe Audience Manager to help identify a unique visitor across domains.

Cookie	Duration	Description
_fbp	3 months	This cookie is set by Facebook to display advertisements when either on Facebook or on a digital platform powered by Facebook advertising, after visiting the website.
fr	3 months	Facebook sets this cookie to show relevant advertisements to users by tracking user behaviour across the web, on sites that have Facebook pixel or Facebook social plugin.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
AMCV_98CF678254E93B1B0A4C98A5AdobeOrg	2 years	No description
AMCVS_98CF678254E93B1B0A4C98A5AdobeOrg	session	No description
DrupalVisitorMobile	session	No description available.
FASRV	session	No description available.
FORMASSEMBLY	session	No description available.
prism_798681331	1 month	No description

NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain Neurostimulator

Press Release

NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain Neurostimulator

NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting

NeuroPace Launches Next Generation RNS System, the World’s Only Brain-Computer Interface for the Treatment of Refractory Epilepsy

NeuroPace Unveils 8-Year Prospective Clinical Outcomes and Groundbreaking Research Using Deep Learning Algorithms to Identify Seizure Biomarkers

NeuroPace Closes $74 Million Equity Funding to Accelerate Patient Access to the World’s First Brain-Responsive Neurostimulation System to Treat Epilepsy

NeuroPace Announces 1,000th Patient Treated with RNS System for Medically Refractory Epilepsy

NeuroPace, Inc. Announces Results of 7 Years of Clinical Trial Follow-up Demonstrating 72 Percent Seizure Reduction with the RNS® System – December 4, 2016

NeuroPace RNS® System Honored With Prestigious Award — November 11, 2015

NeuroPace RNS® System Associated with Positive Effects In Memory and Language — October 20, 2015

Long-term Treatment Study Data Show Sustained Effectiveness in Adults — February 2, 2015

PATIENTS

PROVIDERS

CORPORATE

PATIENTS

PROVIDERS

INVESTORS

CORPORATE

Step 1 of 7